We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: pharmacogenomics
MedXY News
EnglishTag

pharmacogenomics

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Harnessing Genomics for Precision Prevention in Psychiatry: Opportunities and Challenges
newsY học dự phòngPolygenic Scores

Harnessing Genomics for Precision Prevention in Psychiatry: Opportunities and Challenges

By MedXY|Sep 2, 2026

Genomic testing holds promise for guiding preventive strategies in psychiatry, particularly in high-risk and clinically uncertain contexts; however, current evidence supports targeted rather than universal approaches.

Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized Therapy
GastroenterologyProton pump inhibitorssurgery

Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized Therapy

By MedXY|Aug 25, 2026

A study reveals a higher prevalence of rapid CYP2C19 metabolizer phenotypes in GERD patients undergoing surgery versus medical therapy, supporting tailored proton pump inhibitor dosing and timely surgical referral.

Precision Medicine Fails to Improve Postoperative Pain: Insights from the CYP2D6-Guided Opioid Trial
Anesthesiologyopioidspharmacogenomics

Precision Medicine Fails to Improve Postoperative Pain: Insights from the CYP2D6-Guided Opioid Trial

By MedXY|Feb 23, 2026

A randomized clinical trial demonstrates that while CYP2D6 genotyping significantly shifts opioid prescribing patterns for poor and intermediate metabolizers, it does not improve pain control or reduce opioid consumption within the context

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial
newspharmacogenomicstreatment-resistant depression

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial

By MedXY|Nov 14, 2025

In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), wi

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities